RECOVERY & TISSUE REPAIR RESEARCH / MATRIX
Four Compounds, One Repair Question, Four Different Evidence Bases
How BPC-157, GHK-Cu, GLOW, and Wolverine differ in mechanism, evidence maturity, regulatory standing, and the single caution that matters most for each.
The short version
This page lines up BPC-157, GHK-Cu, GLOW, and Wolverine on the dimensions that matter most when reading recovery-and-repair peptide research: mechanism, most-studied use, evidence base, regulatory status, and the single most important caution for each. The short version: all four are studied for tissue repair and regeneration, but they sit at very different evidence stages. GHK-Cu has real, controlled human trials — for topical use only. BPC-157 has broad animal data and just three small human pilot studies. GLOW and Wolverine are combinations of the other compounds with no controlled trial of the blend itself. None of the four is an FDA-approved systemic medicine, and nothing here is medical advice or a recommended dose.
The comparison matrix
| Dimension | BPC-157 | GHK-Cu | GLOW | Wolverine |
|---|---|---|---|---|
| Type | Single pentadecapeptide (15 aa) | Single copper-binding tripeptide | Three-peptide blend (GHK-Cu + BPC-157 + TB-500) | Two-peptide blend (BPC-157 + TB-500) |
| Primary mechanism | Angiogenesis via VEGFR2-Akt-eNOS [4] | Matrix remodeling / collagen synthesis [11] | Combines matrix, angiogenic, and cell-migration signals | Combines angiogenic and cell-migration signals |
| Most-studied use | Gastric ulcer healing, tendon repair (animal models) [5][6] | Topical skin firmness, wrinkle depth, hair density [8][10] | Marketed for skin renewal + tissue repair (no blend trials) | Marketed for tendon/ligament/soft-tissue recovery (no blend trials) |
| Evidence base | Overwhelmingly preclinical; 3 small human pilot studies [1][2] | Real controlled human trials — topical only [8][10][11] | Zero controlled trials of the combination; inherits constituent evidence [13] | Zero controlled trials of the combination; inherits constituent evidence [15] |
| Regulatory status | Not FDA-approved; WADA-prohibited | Topical form is a legal cosmetic ingredient; systemic form unapproved | Not FDA-approved; contains a WADA-prohibited constituent (TB-500) | Not FDA-approved; both constituents WADA-prohibited |
| Key caution | Pro-angiogenic; theoretical cancer concern [4] | Injectable/systemic use unstudied in humans | Untested combination; inherits weakest-part limits [2][13] | Untested combination; theoretical tumor-growth concern [16] |
Mechanism
The four compounds split into two mechanistic families. BPC-157 works primarily through angiogenesis — new blood-vessel formation via VEGFR2 up-regulation and the downstream VEGFR2-Akt-eNOS pathway [4] — plus growth-hormone-receptor sensitization in tendon fibroblasts and modulation of nitric-oxide and neurotransmitter systems [7]. GHK-Cu works through matrix remodeling: it is a copper chaperone that stimulates fibroblast synthesis of collagen, elastin, and glycosaminoglycans while rebalancing matrix metalloproteinases, altering expression of roughly 31.2% of human genes at a 50%-or-greater threshold [9][11]. TB-500 (present in both blends) works through a third mechanism entirely — actin sequestration that governs cell migration, distinct from both of the others [16]. GLOW stacks all three mechanisms; Wolverine stacks the angiogenic and cell-migration mechanisms without the matrix-remodeling one.
Most-studied use
BPC-157's foundational and still-largest literature is gastric-ulcer protection and tendon repair, both almost entirely in rats [5][6]. GHK-Cu's largest and best-controlled body of evidence is topical dermatology and hair growth — collagen synthesis, wrinkle depth, and a 45-person controlled hair-growth trial [8][10][11]. GLOW is marketed for a combined skin-renewal-plus-repair use that has literally never been tested as a blend; the closest thing to blend-level evidence is a 2026 review that names all three constituents without testing them together [13]. Wolverine is marketed specifically for tendon, ligament, and soft-tissue recovery — the research-community pairing most closely tied to BPC-157's original tendon-repair signal, again with zero trials of the pairing itself [15].
Evidence base
This is where the four genuinely separate. GHK-Cu has the deepest human evidence on this desk — small but real controlled trials, including a 45-patient randomized hair-growth trial [10] and multiple topical dermatology studies [8][11] — though almost entirely for topical use. BPC-157 has broad rodent evidence and exactly three small human pilot studies, one involving two adults [1][2]. GLOW and Wolverine have no evidence of their own: every claim about either blend is an extrapolation from the constituent literature, and the one review that discusses the constituents together explicitly frames unapproved peptide combinations as scarce on human safety data [13]. A dedicated systematic review of BPC-157 in sports medicine — 36 studies, only one in humans — found no clinical safety data and does not mention TB-500 or combination use at all [15].
Regulatory status
None of the four compounds is approved by the FDA as a systemic medicine. GHK-Cu's exception is narrow: the topical cosmetic ingredient Copper Tripeptide-1 is legal and widely marketed, but injectable or oral GHK-Cu has no approved pathway. BPC-157 is a research chemical only; in 2023 the FDA placed it in a category of bulk drug substances it identified as not eligible for pharmacy compounding pending further evaluation. TB-500 — present in both GLOW and Wolverine — is likewise an unapproved research chemical and, along with BPC-157, is prohibited in sport at all times by the World Anti-Doping Agency. GHK-Cu is not currently itemized on the WADA Prohibited List, though its catch-all S0 category can apply.
Key caution
Each compound carries a defining caveat. For BPC-157, it is the combination of an extremely thin human evidence base with a strong pro-angiogenic mechanism that raises a theoretical cancer concern [4][2]. For GHK-Cu, it is the gap between its genuine topical safety record and the complete absence of human data for injectable or systemic use. For GLOW, it is that the blend itself has never been tested and its evidence ceiling is set by its weakest-studied constituent, BPC-157 [2][13]. For Wolverine, it is a theoretical tumor-growth concern tied to TB-500's parent protein, thymosin beta-4, layered onto the same untested-combination problem [16][15]. Reading the four together, the pattern is consistent: more components means more marketing claims, not more evidence.